<DOC>
	<DOCNO>NCT01790854</DOCNO>
	<brief_summary>Aim : verify acute phase ACS acute coronary syndrome ( 1-months ) , 1 12 month reduction maintenance dose prasugrel 10 mg 5 mg/day may reduce bleed event ( 5 mg v 10 mg ) . All patient treat 325 mg aspirin follow maintenance dosage 100 mg aspirin least 1 year . At baseline ( 60 mg load dose prasugrel ) 1 month ( 7 day randomization 10 5 mg prasugrel ) patient undergo light transmittance aggregometry ( LTA ) test evaluate residual platelet reactivity ( pharmacodynamic effect ) .</brief_summary>
	<brief_title>BLeeding Events Maintenance DoSe PraSugrel</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>ACS patient treat PCI ( percutaneous coronary intervention ) dual antiplatelet therapy ( DAPT : aspirin plus prasugrel ) . Informed write consent Age &lt; 18 year Active bleeding ; bleed diathesis ; coagulopathy History gastrointestinal genitourinary bleeding &lt; 2 month Major surgery last 6 week History intracranial bleed structural abnormality Suspected aortic dissection Any previous TIA ( transient ischemic attack ) /stroke Administration week index event clopidogrel , ticlopidine , prasugrel , ticagrelor , thrombolytic , bivalirudin , lowmolecular weight heparin fondaparinux . Known relevant hematological deviation : Hb &lt; 10 g/dl , Thrombocytopenia . &lt; 100x10^9/l Use coumadin derivative within last 7 day Chronic therapy prasugrel ticagrelor Known malignancy comorbid condition life expectancy &lt; 1 year Known severe liver disease , severe renal failure Known allergy study medication Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prasugrel</keyword>
	<keyword>antiplatelet</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
</DOC>